Department of Dermatology and Venereology, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey.
Department of Bioistatistics, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey.
Dermatol Ther. 2021 Jan;34(1):e14623. doi: 10.1111/dth.14623. Epub 2020 Dec 11.
There have been a number of investigations of the efficacy and safety of etanercept. This study was performed to obtain long-term drug survival data (ie, time to drug discontinuation) for etanercept, and the reasons for its discontinuation. The study population consisted of patients with psoriatic arthritis and psoriasis followed up by our clinic, registered in the Turkish Psoriasis Registry (PSR-TR) and treated with etanercept for at least 4 weeks between January 1, 2005, and January 31, 2020. The efficacy of etanercept was evaluated in terms of the Psoriasis Area and Severity Index (PASI) 75, PASI 90 and PASI 100 response rates at 12, 24, 36, and 48 weeks, and annually thereafter. The behaviors of the patients with respect to the use of etanercept, and the outcomes of those who continued to use it during the COVID-19 pandemic, were also investigated.
已经有许多关于依那西普疗效和安全性的研究。本研究旨在获得依那西普的长期药物生存数据（即药物停药时间）及其停药原因。研究人群包括我们诊所随访的患有银屑病关节炎和银屑病的患者，这些患者在 2005 年 1 月 1 日至 2020 年 1 月 31 日期间，在土耳其银屑病登记处（PSR-TR）登记，并接受依那西普治疗至少 4 周。依那西普的疗效根据治疗 12、24、36 和 48 周及此后每年的银屑病面积和严重程度指数（PASI）75、PASI 90 和 PASI 100 缓解率进行评估。还调查了患者使用依那西普的情况，以及在 COVID-19 大流行期间继续使用依那西普的患者的结局。
